Lutetium-177 DOTA satoreotide

N/A

Report date: 2025/11/28 15:16:15
NME

Base Information

Drug NameLutetium-177 DOTA satoreotide
Drug Alias NameLutetium-177 satoreotide tetraxetanLutetium-177-DOTA-satoreotide177Lu-satoreotide177Lu-Satoreotide tetraxetanSOMther +[13] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionIonising radiation emittersSomatostatin receptor 2 antagonists
TargetsSomatostatin receptor 2
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Small Cell Lung CarcinomaBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesAustralia +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOctreoPharm Sciences GmbH
China Registration ClassN/A

Develop Information

Active CompaniesAriceum Therapeutics Australia Pty LtdAriceum Therapeutics GmbHUniversity Hospital Basel
Inactive CompaniesIpsen
Active IndicationsPancreatic neuroendocrine tumors (pNET)Small Cell Lung CarcinomaMeningioma
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A